Literature DB >> 27697065

Gender Disparity in Lipid Target Achievements in High and Very High Atherosclerotic Cardiovascular Disease Risk Patients in the Arabian Gulf.

Ibrahim Al-Zakwani, Abdullah Shehab, Ali T Al-Hinai, Wael Al Mahmeed, Mohamed Arafah, Omer Al Tamimi, Mahmoud Al Awadhi, Faisal Al Anazi, Haitham Amin, Khalid Al Nemer, Shorook Al Herz, Othman Metwally, Akram Alkhadra, Mohammed Fakhry, Hossam Elghetany, Abdel Razak Medani, Afzal Hussein Yusufali, Obaid Al Jassim, Omar Al Hallaq, Fahad Omar, Ahmed S Baslaib, Khalid Al Waili, Khamis Al Hashmi, Vasilios G Athyros, Khalid Al Rasadi1.   

Abstract

BACKGROUND: Few studies assessed gender disparity in lipid goal attainment in the Arabian Gulf. Hence, we estimated gender gaps in lipid target achievements among patients at high and very high atherosclerotic cardiovascular disease (ASCVD) risk in the Centralized Pan-Middle East Survey on the undertreatment of hypercholesterolemia (CEPHEUS).
METHODS: The study (conducted between November 22, 2009 and July 7, 2010) included 4,384 patients (≥18 years) on lipid lowering drugs at high and very ASCVD risk status from outpatient clinics of 177 specialists and primary care physicians in 6 Arabian Gulf countries.
RESULTS: The overall mean age was 57±11 years and 40% (n=1763) were women. Women were more likely to have diabetes mellitus (84 vs 71%; p <0.001) and metabolic syndrome (49 vs 35%; p <0.001) compared with males. Women were less likely to achieve their low-density lipoprotein cholesterol (LDLC) (28 vs 32%; p = 0.002), high-density lipoprotein cholesterol (HDL-C) (42 vs 50%; p <0.001), and apolipoprotein B (Apo B) (38 vs 42%; p = 0.015) targets compared with men. In the very high ASCVD risk cohort, women were significantly less likely to achieve their LDL-C (20 vs 30%; p <0.001), non- HDL-C (34 vs 39%; p = 0.001) and Apo B (34 vs 41%; p <0.001) therapeutic targets compared with men.
CONCLUSION: Women in the Arabian Gulf were less likely to achieve their lipid targets than men. The difference was more significant in the very high ASCVD risk group.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27697065     DOI: 10.2174/1570161114666161003095139

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  2 in total

1.  Statin Therapy and Low-Density Lipoprotein Cholesterol Reduction after Acute Coronary Syndrome: Insights from the United Arab Emirates.

Authors:  Abdulla Shehab; Akshaya Srikanth Bhagavathula
Journal:  Heart Views       Date:  2020-06-29

2.  Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study.

Authors:  Ibrahim Al-Zakwani; Fatma Al-Mahruqi; Khalid Al-Rasadi; Abdullah Shehab; Wael Al Mahmeed; Mohammed Arafah; Ali T Al-Hinai; Omer Al Tamimi; Mahmoud Al Awadhi; Raul D Santos
Journal:  Lipids Health Dis       Date:  2018-02-05       Impact factor: 3.876

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.